Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 1 December 2023 to 30 September 2024
  • Awards: Pump-priming Awards

This project aims to establish the Presto-Tango system within the BHF CRE. Presto-Tango is designed for high-throughput screening of GPCR receptors through β-arrestin recruitment. This assay has been developed to identify inhibitors of GPCRs, and to identify agonists of orphan GPCRs. The Presto-Tango system, once established, will be used within our laboratory to identify anti-inflammatory molecules targeting chemokine receptor GPCRs. This project will support the further characterisation of prospective anti-inflammatory peptide therapeutics against previously untested chemokine receptors. The Presto-Tango kit contains 300+ GPCR constructs and is available as a resource for BHF CRE researchers interested in GPCRs. Details of the kit can be found here: Addgene: Roth Lab PRESTO-Tango GPCR Kit

Schematic depiction of the Presto-Tango β-arrestin recruitment assay

Schematic depiction of the Presto-Tango β-arrestin recruitment assay. HTLA cells, expressing a β-arrestin2-TEV protease fusion protein and a luciferase reporter gene, are transiently transfected with a Tango GPCR construct. 1) The G-protein coupled receptor (GPCR) is activated through agonist ligand binding. 2) β-arrestin2- TEV (tobacco virus nuclear inclusion a endopeptidase) is recruited to the GPCR C-terminus. 3) The TEV protease bound to the β-arrestin2 cleaves the TEV cleavage site, releasing the tTA (tetracycline transactivator protein). 4) The tTA translocates to the nucleus, activating luciferase production.